Effects and Safety of Repeated 131I metaiodophenylguanitidine (MIBG) in Patients with Malignant Pheochromocytoma and Paraganglioma

Effects and Safety of Repeated 131I metaiodophenylguanitidine (MIBG) in Patients with Malignant Pheochromocytoma and Paraganglioma - RIMAP Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007179

Enrollment

Registered

2012-02-10

Start date

2000-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Pheochromocytoma and Malignant Paraganglioma

Interventions

Patients with malignant pheochromocytoma and paraganglioma will have 100 to 150 mCi of 131I MIBG radiotherapy10. These patients will have repeated 131I MIBG radiotherapy within 6 months after the init

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with malignant pheochromocytoma and paraganglioma who will undergo I-131 MIBG therapy and have follow-up imaging studies.

Exclusion criteria

Exclusion criteria: life expectancy less than 3 month due to other co-morbidity very low ADL ability age < 18 years, pregnant or breast-feeding inability to obtain informed consent claustrophobia

Design outcomes

Primary

Measure	Time frame
We will evaluate therapeutic response using blood work, urine correction, clinical symptoms, whole-body CT, F-18 FDG PET/CT, and I-131 MIBG before and after I-131 MIBG radiotherapy. We will also evaluate the adverse effects using blood work, symptoms, and other imaging studies.	—

Countries

Japan

Contacts

Public ContactKeiichiro Yoshinaga, M.D., Ph.D, F.A.C.C..

Hokkaido University Graduate School of Medicine, Department of Molecular Imaging

kyoshi@med.hokudai.ac.jp011-706-5151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026